Market cap
$46 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -17.21 | 9.18 | 7.73 |
| Net Profit | 34.61 | -220.03 | -132.96 | -7.18 | -0.05 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -- | -- | -12,122.39 | -- | -- |
| Net Margin
| -- | 3,300.76 | -21,821.64 | -- | -- |
| Return on equity
| -100.55 | -123.56 | -41.31 | -123.34 | -86.40 |
| Return on Capital
| -100.03 | -110.99 | -- | -122.95 | -86.13 |
| Return on Assets
| -60.24 | -76.80 | -47.04 | -24.58 | -76.64 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.01 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
--
|
-122.95
|
-86.13
|
-91.01
|
-129.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-41.31
Lower than Peers by 0.91
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-41.31
|
-123.34
|
-86.40
|
-91.91
|
-154.68
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-47.04
Lower than Peers by 16.06
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-47.04
|
-24.58
|
-76.64
|
-79.49
|
-101.92
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-12,122.39
Lower than Peers by 12,038.77
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-12,122.39
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-21,821.64
Lower than Peers by 21,728.97
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-21,821.64
|
--
|
--
|
--
|
3,300.76
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.19
Lower than Peers by 0.19
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-0.19
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
EBIT Growth
-17.21
Lower than Peers by 16.41
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-17.21
|
43.10
|
-3.92
|
-29.81
|
31.58
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-132.96
Lower than Peers by 125.66
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-132.96
|
41.76
|
-4.84
|
-18.09
|
24.20
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
--
|
0.01
|
0.00
|
0.00
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
--
|
0.01
|
0.00
|
0.00
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.30
Lower than Peers by 2.51
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
3.30
|
4.17
|
6.46
|
10.69
|
4.12
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
3.30
Lower than Peers by 2.39
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
3.30
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-13.28
Lower than Peers by 11.19
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-13.28
|
--
|
-86.94
|
-66.51
|
--
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
--
|
4,465.87
|
3,166.22
|
4,235.09
|
3,414.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
0.88
Lower than Peers by 4.30
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
0.88
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.64
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
-0.64
|
1.11
|
0.77
|
1.73
|
0.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
46
Lower than Peers by 100
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Aileron Therapeutics (ALRN)
|
46
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|